Sorafenib Approved in Japan for the Treatment of Advanced Liver Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Sorafenib Approved in Japan for the Treatment of Advanced Liver Cancer

NEW YORK -- May 20, 2009 -- The Ministry of Health, Labour and Welfare (MHLW) has approved sorafenib (Nexavar) tablets for the treatment of unresectable hepatocellular carcinoma (HCC).

The decision was based on positive data from the international, phase 3, double-blind, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial that evaluated more than 600 patients who received no prior systemic therapy.

The study found that sorafenib extended overall survival by 44% in patients with HCC versus placebo.

The most common adverse reactions which were considered to be related to sorafenib are fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhoea, anorexia, nausea, and abdominal pain

SOURCE: Bayer

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities